Amarin Corporation plc, each representing one Ordinary Share (AMRN) Company Bio
Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company was founded in 1989 and is based in Dublin, Ireland.
AMRN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Amarin Corp Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Amarin Corp Plc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Amarin Corp Plc ended up being:
Its compound free cash flow growth rate, as measured over the past 0.52 years, is -0.94% -- higher than only 0.19% of stocks in our DCF forecasting set.
Relative to other stocks in its sector (Healthcare), Amarin Corp Plc has a reliance on debt greater than merely 10.01% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMRN, try AGHC, ALC, ATRS, MOR, and PACB.
The markets might be in turmoil, but spare a thought for the current woes at biotech Amarin (AMRN). Over the past 7 trading sessions, shares have retreated by 44% as investors charged to the exit doors following a botched date in court.Last week, an appeals court rejected Amarin’s appeal concerning a
Background If unaware, the title is a quote from Yogi Berra, that great baseball player and common-man philosopher. So, when the U.S. Court of Appeals affirmed the decision of the U.S. District Court for the district of Nevada and ruled Amarin’s (AMRN) patents for Vascepa obvious and, thus, invalid, it...
After remaining steady in the first three sessions of the week ended Sept. 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off. Barring anything COVID-19-related , the news flow was fairly light ahead of the Labor Day holiday. Amarin Corporation plc (NASDAQ: AMRN ) took a severe beating after losing a patent appeal related to its synthetic fish oil pill Vascepa. The stock lost over 40% during the week, attributable primarily to the adverse ruling and to a smaller extent to the market sell-off. Here are the key catalysts for the unfolding week. Conferences Citi's 15th Annual BioPharma Conference: Sept. 8-11 Wells Fargo 2020 Virtual Healthcare Conference: Sept. 9-10 Baird 2020 Global Healthcare Conference: Sept. 9-10 BTIG Virtual Biotechnology Conference...